DF/HCC Renal Cancer SPORE

描述（由申请人提供）：本申请代表了新成立的丹娜-法伯哈佛癌症中心（DF/HCC）和贝斯以色列女执事医疗中心的肾癌项目发展中肾癌研究卓越专业项目的创建。DF/HCC肾癌孢子包括来自所有哈佛附属医院的研究人员-贝斯以色列女执事医疗中心，丹娜-法伯癌症研究所，马萨诸塞州总医院，布里格姆妇女医院，儿童医院医疗中心，以及哈佛公共卫生学院。通过该应用程序支持五个主要项目，包括：1)识别早期发现和监测高危RCC人群的标记；2)抑制vhl调控的生长因子通路治疗RCC；3)射频消融联合抗血管/抗血管生成治疗RCC；4)确定RCC预后和治疗反应性的分子和免疫学相关因素；5)树突状细胞/肿瘤融合与IL-12联合作为RCC的新型免疫疗法。这些项目由四个核心集成。它们是：1)行政、评价和规划；2)生物统计学;3)组织采集，病理和临床数据，4)监测。这个《孢子》应用程序概述了一个发展项目计划，其中包括一个项目选择和审查计划，以及八个可以考虑支持的样本项目。我们还包括一个职业发展奖励计划，该计划概述了识别、支持和审查肾癌领域有才华的年轻研究者的机制。DF/HCC肾癌孢子的总体目标是将生物学和技术进步转化为对肾癌患者有临床意义的进展。

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence in Renal Cancer originating from the Renal Cancer Program-in-Development of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Renal Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Identification of markers for early detection and monitoring of high-risk RCC populations; 2) Inhibition of VHL-regulated growth factor pathways for treatment of RCC; 3) Combination radiofrequency ablation and antivascular/anitangiogenesis therapy for RCC; 4) Identification of molecular and immunologic correlates of RCC prognosis and responsiveness to therapy, and 5) Dendritic cell/tumor fusions in conjunction with IL-12 as novel immunotherapy for RCC. These projects are integrated by four cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; 3) Tissue Acquisition, Pathology and Clinical Data, and 4) Monitoring. This SPORE application outlines a Developmental Projects Program which includes a plan for selection and review of projects, and eight sample projects that could be considered for support. We also include a Career Development Award Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Renal Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with renal cancer.